Associated Papers
Molecular mechanisms of SLC30A10-mediated manganese transport.
Shen X et al.
Nature Communications, 2025
41022720 (PubMed )
Supplement: 41467_2025_63616_MOESM1_ESM.pdf
Consensus of Expert Opinion for the Diagnosis and Management of Hypermanganesaemia With Dystonia 1 and 2.
Fang S et al.
Journal of Inherited Metabolic Disease, 2025
40320765 (PubMed )
Supplement: JIMD-48-0-s001.xlsx › Sheet1
Clinical Profile and Treatment Outcomes of Hypermanganesemia with Dystonia 1 and 2 among 27 Indian Children.
Garg D et al.
Movement Disorders Clinical Practice, 2022
Treatable Hereditary Manganese Transport Disorder: Novel SLC30A10 Mutation and its Characteristic Neuroimaging Appearance in Two Siblings.
Santhakumar S et al.
Journal of Pediatric Genetics, 2021
Genetic Disorders of Manganese Metabolism.
Anagianni S et al.
Current Neurology and Neuroscience Reports, 2019
Disease-Homologous Mutation in the Cation Diffusion Facilitator Protein MamM Causes Single-Domain Structural Loss and Signifies Its Importance.
Barber-Zucker S et al.
Scientific Reports, 2016
Syndrome of Hepatic Cirrhosis, Dystonia, Polycythemia, and Hypermanganesemia Caused by Mutations in SLC30A10, a Manganese Transporter in Man.
Tuschl K et al.
American Journal of Human Genetics, 2016
Current understanding of ZIP and ZnT zinc transporters in human health and diseases.
Kambe T et al.
Cellular and Molecular Life Sciences : Cmls, 2014
Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man.
Tuschl K et al.
American Journal of Human Genetics, 2012
Select a paper to view details